Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Al-Razi Medical Co. operates in the pharmaceuticals sector, focusing on the production and distribution of generic medications primarily in Saudi Arabia. The company's competitive position is bolstered by its ability to offer a diverse range of affordable healthcare products, which are essential in a market characterized by rising healthcare costs.
Al-Razi Medical Co. generates revenue through the sale of generic medications, which are priced competitively to capture market share in a cost-sensitive environment. The company benefits from economies of scale in production, allowing it to maintain a gross margin of 25.9%. Its established relationships with healthcare providers and pharmacies enhance its distribution capabilities.
Changes in healthcare regulations affecting generic drug pricing
Market demand for affordable pharmaceuticals in Saudi Arabia
Competitive pricing strategies from larger pharmaceutical companies
New product approvals or launches in the generic segment
Regulatory changes that could affect pricing and market access for generic drugs
Technological advancements in drug development that may outpace current offerings
Intensifying competition from both local and international pharmaceutical companies
Potential entry of larger firms into the generic market segment
Low liquidity with a current ratio of 1.47, which may limit operational flexibility
Potential cash flow constraints given the operating cash flow is currently at $0.0B
moderate - The demand for pharmaceuticals is generally stable, but economic downturns can impact consumer spending on healthcare products.
Low - Al-Razi Medical Co. is less sensitive to interest rates as its financing needs are modest, given its low debt levels.
minimal - The company operates with a debt/equity ratio of 0.51, indicating a conservative capital structure.
value - The low price-to-sales ratio of 0.6x may attract value investors looking for undervalued opportunities in the healthcare sector.
moderate - The stock has shown a 1-year return of -26.9%, indicating potential volatility in market perception.